Shanghai: July, 28 2009: Hutchison MediPharma Limited (‘Hutchison MediPharma’), announced today that its HMPL-012 project received grant support from The Science and Technology Commission of Shanghai Municipality. The grant comes from the 2009 Shanghai Scientific Innovation Program supporting the key biomedical programs in Shanghai. HMPL-012 (Sulfatinib) is a novel VEGFR/FGFR inhibitor that targets tumor angiogenesis. Sulfatinib demonstrated anti-tumor activity against a variety of human tumors in xenograft models. An Investigative New Drug application has been submitted to the Chinese State Food and Drug Administration (SFDA) and is currently under review by the SFDA. This is Hutchison MediPharma’s second drug development program receiving government support and imbursement since HMPL-004. This marks another high level of government recognition in Hutchison MediPharma’s innovative drug R&D research.